Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRGN-2009 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Precigen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
PRGN-2009 + pembrolizumab is a combination therapy under investigation for the treatment of human papillomavirus (HPV)-associated cancers, particularly recurrent or metastatic cervical cancer. PRGN-2009 is an off-the-shelf therapeutic vaccine based on a gorilla adenovirus vector that delivers HPV type 16 and 18 antigens to induce a de novo HPV-specific immune response by transgene expression in antigen-presenting cells. Pembrolizumab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, acting as an immune checkpoint inhibitor to enhance anti-tumor immunity. The combination aims to leverage both direct immunization against HPV antigens and checkpoint blockade to improve anti-tumor responses in patients with advanced or resistant disease[2][5][6].
- Brand names
- Keytruda
- Other names
- none
02
Targets
HPV16 E6 oncoproteinPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on PRGN-2009 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRGN-2009 + pembrolizumab.